Kent McParland

Kent McParland discloses dealings in Abattis Bioceuticals Corp. to SEDI. Between 7 May 2018 and 22 November 2018, the trades on record add up to 4 filings.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

The newest entry dates from 26 November 2018: a share grant of €8,961, in Abattis Bioceuticals Corp. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.